NCT04163900终止3 期
A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- NuCana plc
- 入组人数
- 773
- 试验地点
- 125
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
The primary hypotheses are:
- The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care
- The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
Imaging scans will be assessed by blinded independent review according to RECIST v1.1
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent and authorization to use and disclose health information.
- •Ability to comprehend and willingness to comply with the requirements of this protocol, including the QoL questionnaires.
- •Female or male patients aged ≥18 years.
- •Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract (including gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers) that is locally advanced, unresectable or metastatic (AJCC edition 8, 2018). Patients with measurable (as per RECIST v1.1 criteria) or non-measurable disease are permitted.
- •Life expectancy ≥16 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Adequate biliary drainage with no evidence of ongoing infection. If applicable, treatable and clinically-relevant biliary duct obstruction has been relieved by internal endoscopic drainage/stenting at least 2 weeks previously or by palliative bypass surgery or percutaneous drainage prior to study treatment, and the patient has no active or suspected uncontrolled infection. Patients fitted with a biliary stent should be clinically stable and free of signs of infection for ≥2 weeks prior to study treatment. Patients with improving biliary function who meet all other inclusion criteria may be re-tested during the screening window.
- •Adequate bone marrow, hepatic, and renal function, as evidenced by:
- •Absolute neutrophil count (ANC) ≥1,500/μL without colony-stimulating factor support
- •Platelet count ≥100,000/μL
- •Haemoglobin ≥9 g/dL without need for haematopoietic growth factor or transfusion support in prior 2 weeks
- •Total bilirubin <2 × upper limit of normal (ULN); does not apply to patients with Gilbert's syndrome. Consistent with inclusion criterion 7, patients whose whole bilirubin and biliary function is recovering may be re-tested during the screening period.
- •Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <5 × ULN
- •Creatinine clearance ≥45 mL/min actual or calculated by the Cockcroft-Gault method
- •International normalized ratio (INR) <1.5 and activated partial thromboplastin time (aPTT) <1.5 × ULN; does not apply to patients on an anti-coagulant with stable dose 28 days prior to first dose.
- •QTc interval <450 msec (males) or <470 msec (females), in the absence of bundle branch block. In the presence of bundle branch block with consequent QTc prolongation, patients may be enrolled based on a careful risk-benefit assessment.
- •Human Immunodeficiency Virus-infected patients who are healthy and have a low risk of Acquired Immunodeficiency Syndrome-related outcomes may be included in this study.
- •Female patients of child-bearing potential (i.e., all women except those who are post-menopausal for ≥1 year or who have a history of hysterectomy or surgical sterilization) must have a negative pregnancy test within 3 days prior to the first study drug administration. All patients of child-bearing potential must agree to practice true abstinence or to use two highly effective forms of contraception, one of which must be a barrier method of contraception, from the time of screening until 6 months after the last dose of study medication.
- •Male patients with a female partner must either have had a successful vasectomy or they and their female partner meet the criteria above (not of childbearing potential or practicing highly effective contraceptive methods).
排除标准
- •Combined or mixed hepatocellular/cholangiocarcinoma.
- •Prior systemic therapy for advanced or metastatic biliary tract cancer. However, prior chemotherapy in the adjuvant setting or low-dose chemotherapy given in conjunction with radiotherapy in the adjuvant setting and completed at least 6 months prior to enrolment is permitted. The following prior interventions are allowed provided the patient has fully recovered:
- •Surgery: non-curative resection with macroscopic residual disease or palliative bypass surgery. Patients who have previously undergone curative surgery must now have evidence of non-resectable disease requiring systemic chemotherapy.
- •Radiotherapy: prior radiotherapy (with or without radio-sensitizing low-dose chemotherapy) for localized disease and there is now clear evidence of disease progression requiring systemic chemotherapy.
- •Photodynamic therapy: prior photodynamic therapy for localized disease with no evidence of metastatic disease or for localized disease to relieve biliary obstruction in the presence of metastatic disease provided there is now clear evidence of disease progression requiring systemic chemotherapy.
- •Palliative radiotherapy: palliative radiotherapy provided that all adverse events have resolved and the patient has measurable disease outside the field of radiation.
- •Prior treatment with or known hypersensitivity to NUC-1031, gemcitabine, cisplatin or other platinum-based agents or history of allergic reactions attributed to any parenteral excipients (e.g. dimethylacetamide [DMA], Cremophor EL, Polysorbate 80, Solutol HS 15).
- •Symptomatic central nervous system or leptomeningeal metastases.
- •History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, surgically excised or potentially curatively treated ductal carcinoma in situ of the breast, or low grade prostate cancer or patients after prostatectomy not requiring treatment. Patients with previous invasive cancers are eligible if treatment was completed more than 3 years prior to initiating the current study treatment, and the patient has had no evidence of recurrence since then.
- •Concurrent serious (as deemed by the Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.
- •Congenital or acquired immunodeficiency (e.g., serious active infection with HIV). As per inclusion criterion 10, patients with HIV who are healthy and have a low risk of AIDS related outcomes are eligible.
- •Other acute or chronic medical, neurological, or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
- •Prior exposure to another investigational agent within 28 days prior to randomization.
- •Major surgery within 28 days prior to randomization; patient must have completely recovered from any prior surgical or other procedures.
- •Pregnant or breastfeeding.
- •Residual toxicities from prior treatments or procedures which have not regressed to Grade ≤1 severity (CTCAE v5.0), except for alopecia or ≤ Grade 2 peripheral neuropathy.
- •Concomitant use of drugs at doses known to cause clinically relevant prolongation of QT/QTc interval.
- •Administration of a live vaccination within 28 days prior to randomization.
- •Ongoing or recent (≤6 months) hepatorenal syndrome.
研究组 & 干预措施
A - NUC-1031 and cisplatin
Experimental
725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
干预措施: NUC-1031 (Drug)
A - NUC-1031 and cisplatin
Experimental
725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
干预措施: Cisplatin (Drug)
B - gemcitabine and cisplatin
Active Comparator
1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
干预措施: Gemcitabine (Drug)
B - gemcitabine and cisplatin
Active Comparator
1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
干预措施: Cisplatin (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: From the date of randomization until the date of death from any cause, assessed up to 12 months on average
The median time, in months, from the date of randomization to the date of death from any cause. For patients who were alive at the time of a data cut-off or were permanently lost to follow up, duration of OS was censored at the date at which they were last known to be alive.
Objective Response Rate (ORR)
时间窗: Evaluated at Screening (baseline) then every 9 weeks from treatment start (C1D1), or every 12 weeks if treatment is stopped with no evidence of progression, until disease progression or death from any cause up to the end of study, an average of 6 months.
Percentage of patients achieving a confirmed complete response (CR) or partial response (PR) to treatment as assessed by blinded independent review according to RECIST v1.1 criteria. ORR = patients with CR + patients with PR, where" CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters This outcome was assessed in the population of patients with measurable disease at baseline who were also randomized ≥28 weeks before the data cut-off (ITTMD28). Patients were to receive a confirmatory scan 28-42 days after response is first observed.
次要结局
未报告次要终点
研究者
研究点 (125)
Loading locations...
相似试验
已完成
3 期
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract CancerBiliary Tract CancerNCT02182778Kansai Hepatobiliary Oncology Group246
终止
3 期
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal CancerMetastatic Nasopharyngeal CarcinomaMetastatic Nasopharyngeal Keratinizing Squamous Cell CarcinomaMetastatic Nasopharyngeal Nonkeratinizing CarcinomaMetastatic Nasopharyngeal Undifferentiated CarcinomaNasopharyngeal Nonkeratinizing CarcinomaRecurrent Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Keratinizing Squamous Cell CarcinomaRecurrent Nasopharyngeal Undifferentiated CarcinomaStage IV Nasopharyngeal Carcinoma AJCC v8Stage IVA Nasopharyngeal Carcinoma AJCC v8Stage IVB Nasopharyngeal Carcinoma AJCC v8NCT04458909National Cancer Institute (NCI)15
尚未招募
Unknown
Phase III study of gemcitabine, cisplatin plus S-1 combination therapy versus gemcitabine, cisplatin plus immune checkpoint inhibitor combination therapy in advanced biliary tract cancer.advanced biliary tract cancerJPRN-UMIN000051689Yamaguchi University460
Unknown
3 期
Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown PrimaryCarcinomaNCT00126269Gustave Roussy, Cancer Campus, Grand Paris192
已完成
3 期
A Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancerung (small cell) cancerLung (small cell)CancerISRCTN39679215CRI CSG and London Lung Cancer Group (UK)241